Comparison of Proportional Assist Ventilation And Neurally Adjusted Ventilator Assist

Breathing Pattern Variability, Respiratory Discomfort and Work of Breathing in Proportional Assist Ventilation And Neurally Adjusted Ventilator Assist

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02056093

Acronym

PAVANAVA

Enrollment

Registered

2014-02-05

Start date

2013-09-30

Completion date

2014-02-28

Last updated

2014-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Respiratory Failure

Keywords

NAVA - PAV- Breathing Variability - Asynchrony

Brief summary

In spontaneously breathing mechanically ventilated patients, the adequacy between the patient's demand and the level of respiratory support delivered by the ventilator is a major clinical issue. Neurally adjusted ventilator assist (NAVA) and proportional assist ventilation (PAV) have been developed to adapt the level of assistance to the patient's demand. These two modes have been compared to pressure support ventilation (PSV) but have not been compared to each other.

Interventions

DEVICEPSV mode

Application of PSV in all patients

DEVICEPAV mode

Application of PAV mode in all patients

DEVICENAVA

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Intubated patients. * Mechanical ventilation for a respiratory reason. * Expected duration of Mechanical ventilation \> 48 hrs. * Spontaneous breathing. * Sedations stopped for more than 24 hours.

Exclusion criteria

* \- Main contra indications to NAVA: gastro-oesophageal surgery in the previous 12 months, oesophageal obstruction, gastro-esophageal bleeding in the previous 30 days, history of esophageal varices, facial trauma or surgery, neuromuscular diseases, individuals with known or suspected phrenic nerve dysfunction. * Main contra indications to PAV: airway leak, body weight \<25 kg, neuromuscular diseases. * Hemodynamic instability defined as the current administration of vasopressors or inotropic drugs. * Severe hypoxemia defined as PaO2/FiO2 ratio \<200. * Decision to withhold life-sustaining treatment. * Pregnant women. * Minors \< 18 years.

Design outcomes

Primary

Measure	Time frame	Description
Breathing pattern variability	February 2014	The coefficient of variation (standard deviation divided by the mean) of the tidal volume (expressed in %)

Secondary

Measure	Time frame	Description
Patient-ventilator asynchrony	February, 2014	Prevalence of ineffective efforts and double triggering (expressed as a number of events per minute)

Other

Measure	Time frame	Description
Electrical diaphragm activity Gas exchange	February 2014	measured by the NAVA probe

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 18, 2026